Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects with Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers

Next Previous
Trial Profile

Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects with Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Satricabtagene autoleucel (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ELIMYN18.2
  • Sponsors CARsgen

Most Recent Events

  • 08 Jan 2025 The protocol has been amended.
  • 20 Jan 2024 Results ( As of May 14, 2023, n=24) assessing safety and efficacy of satri-cel in patients with CLDN18.2-positive advanced GC/GEJ or PC presented at the 2024 Gastrointestinal Cancers Symposium
  • 19 Jan 2024 According to a CARsgen media release, updated results from this trial presented at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top